Physician profile
Madison Gruss
NPI 1588285498
$235.34
in general payments reported to CMS, 2019-2025
8 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $143 · 2022: $92.51.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $70.14 | 2021-2022 | |
| Neurelis, INC. | $45.68 | 2021 | |
| Ironshore Pharmaceuticals INC. | $36.46 | 2022 | |
| Glaxosmithkline, LLC. | $28.10 | 2022 | |
| Merck Sharp & Dohme LLC | $16.79 | 2021 | |
| Seqirus USA INC | $13.46 | 2022 | |
| Sanofi Pasteur INC. | $12.89 | 2021 | |
| Neos Therapeutics, LP | $11.82 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Madison Gruss listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.